Senate health committee chair Bernie Sanders (I-VT) has set Sept. 24 as the date for a high-profile hearing that will feature testimony from Novo Nordisk global CEO Lars Fruergaard Jørgensen on why the company has priced Ozempic and Wegovy dramatically higher in the United States than in other countries. The hearing announcement comes after Jørgensen willingly agreed to participate on a solo panel, prompting Sanders to drop his initial threat to subpoena the company’s U.S. president to appear. Sanders plans...